Open-label, long-term study of coadministration of ezetimibe and atorvastatin in patients with primary hypercholesterolemia who have not reached LDL [low density lipoprotein]-cholesterol target with HMG [3 hydroxy 3 methyl glutaryl]-CoA [coenzyme A] reductase inhibitors.

Trial Profile

Open-label, long-term study of coadministration of ezetimibe and atorvastatin in patients with primary hypercholesterolemia who have not reached LDL [low density lipoprotein]-cholesterol target with HMG [3 hydroxy 3 methyl glutaryl]-CoA [coenzyme A] reductase inhibitors.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2017

At a glance

  • Drugs Atorvastatin; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Acronyms COMPLETED
  • Sponsors Schering-Plough
  • Most Recent Events

    • 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Planned end date changed from 1 May 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 27 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top